lutetium has been researched along with Stomach Neoplasms in 12 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (8.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (16.67) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 3 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bagni, O; D'Agostini, A; Filippi, L; Pirisino, R | 1 |
| Bodeker, KL; Bushnell, DL | 1 |
| Leeuwenkamp, OR; Reed, N; Smith-Palmer, J; Virk, J | 1 |
| Ćwikła, JB; Kolasińska-Ćwikła, A; Maciejkiewicz, KM; Łowczak, A | 1 |
| Boucher, JE; Sommers, R | 1 |
| Costa, FP; de Herder, WW; Feelders, RA; Gumz, B; Kaltsas, G; Kamp, K; Kwekkeboom, DJ | 1 |
| Cives, M; Soares, HP; Strosberg, J | 1 |
| Beck, R; Bruchertseifer, F; Quintanilla-Martinez, L; Seidl, C; Senekowitsch-Schmidtke, R; Zöckler, C | 1 |
| KAWAMURA, K; KITAGAWA, S | 1 |
| Krenning, EP; Kwekkeboom, DJ; Teunissen, JJ | 1 |
| Bakker, WH; de Herder, WW; Krenning, EP; Kwekkeboom, DJ; van Aken, MO; van Essen, M | 1 |
4 review(s) available for lutetium and Stomach Neoplasms
| Article | Year |
|---|---|
Overview and Current Status of Peptide Receptor Radionuclide Therapy.
Topics: Animals; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Radiopharmaceuticals; Receptors, Somatostatin; Stomach Neoplasms | 2020 |
Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
Topics: Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Radioisotopes; Receptors, Peptide; Stomach Neoplasms; Yttrium Radioisotopes | 2018 |
Lutetium lu 177 dotatate (Lutathera) for gastroenteropancreatic neuroendocrine tumors.
Topics: Animals; Clinical Trials as Topic; Heterocyclic Compounds, 1-Ring; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Pancreatic Neoplasms; Peptides, Cyclic; Protein Binding; Stomach Neoplasms | 2018 |
Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials.
Topics: Clinical Trials, Phase III as Topic; Humans; Intestinal Neoplasms; Lutetium; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Radiopharmaceuticals; Randomized Controlled Trials as Topic; Somatostatin; Stomach Neoplasms | 2016 |
1 trial(s) available for lutetium and Stomach Neoplasms
| Article | Year |
|---|---|
Quality of life in patients with gastroenteropancreatic tumors treated with [177Lu-DOTA0,Tyr3]octreotate.
Topics: Adult; Aged; Female; Health Status; Humans; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Quality of Life; Receptors, Peptide; Receptors, Somatostatin; Stomach Neoplasms; Treatment Outcome | 2004 |
7 other study(ies) available for lutetium and Stomach Neoplasms
| Article | Year |
|---|---|
Management of a Patient With Metastatic Gastrointestinal Neuroendocrine Tumor and Meningioma Submitted to Peptide Receptor Radionuclide Therapy With 177 Lu-DOTATATE.
Topics: Aged; Female; Humans; Intestinal Neoplasms; Lutetium; Meningeal Neoplasms; Meningioma; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Radioisotopes; Radionuclide Imaging; Radiopharmaceuticals; Receptors, Peptide; Stomach Neoplasms | 2022 |
Lutetium oxodotreotide (
Topics: Cost-Benefit Analysis; Disease Progression; Follow-Up Studies; Humans; Intestinal Neoplasms; Lutetium; Neoplasm Metastasis; Neuroendocrine Tumors; Octreotide; Organometallic Compounds; Pancreatic Neoplasms; Prognosis; Quality-Adjusted Life Years; Radiopharmaceuticals; Stomach Neoplasms | 2021 |
Targeted Therapy: New Radiolabeled Somatostatin Analogs to Treat Gastroenteropancreatic Neuroendocrine Tumors.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Female; Humans; Intestinal Neoplasms; Lutetium; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Radiopharmaceuticals; Somatostatin; Stomach Neoplasms | 2018 |
Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Topics: Adult; Aged; Bone Neoplasms; Everolimus; Female; Follow-Up Studies; Humans; Immunosuppressive Agents; Intestinal Neoplasms; Liver Neoplasms; Lutetium; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Staging; Neuroendocrine Tumors; Octreotide; Pancreatic Neoplasms; Prognosis; Retrospective Studies; Safety; Sirolimus; Stomach Neoplasms; Survival Rate | 2013 |
177Lu-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to 213Bi-immunotherapy, but causes toxicity not observed with 213Bi.
Topics: Animals; Antibodies, Monoclonal; Bismuth; Blood Cell Count; Cell Line, Tumor; Disease Models, Animal; Drug Stability; Female; Humans; Immunoconjugates; Lutetium; Mice; Peritoneal Neoplasms; Radioimmunotherapy; Radioisotopes; Radiotherapy Dosage; Stomach Neoplasms; Time Factors | 2011 |
STUDIES AND CLINICAL OBSERVATIONS OF INFUSION OF ANTI-CANCEROUS AGENTS INTO LYMPH VESSEL SYSTEM.
Topics: Gastrectomy; Gold Isotopes; Humans; Infusions, Parenteral; Injections, Intralymphatic; Lutetium; Lymph Node Excision; Lymphatic Metastasis; Lymphatic System; Mononuclear Phagocyte System; Radioisotopes; Serum Albumin; Serum Albumin, Radio-Iodinated; Stomach Neoplasms; Thoracic Duct; Yttrium Isotopes | 1964 |
Peptide receptor radionuclide therapy with 177Lu-octreotate in patients with foregut carcinoid tumours of bronchial, gastric and thymic origin.
Topics: Adult; Aged; Bronchial Neoplasms; Carcinoid Tumor; Disease Progression; Female; Humans; Lutetium; Male; Medical Oncology; Middle Aged; Octreotide; Peptides; Radioisotopes; Remission Induction; Stomach Neoplasms; Thymus Neoplasms; Treatment Outcome | 2007 |